Cover Image
Market Research Report

Global Addison's Disease Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 835745
Published Content info 118 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Addison's Disease Therapeutics Market 2019-2023
Published: April 26, 2019 Content info: 118 Pages
Description

About this market

The favorable reimbursement scenario is one of the key factors expected to trigger the market growth during the forecast period. Reimbursement is quite essential for ensuring wider patient access to the Internet. Insurers are increasingly providing complete reimbursement for most of the drugs indicated for the treatment of adrenal insufficiency. In addition, governments and healthcare agencies are further investing a huge amount of money in improving national or regional health. As a result, the supporting reimbursement policies are expected to contribute significantly to the Addison's disease therapeutics market growth during the forecast period. Technavio's analysts have predicted that the Addison's disease therapeutics market will register a CAGR of nearly 4% by 2023.

Market Overview

Special drug designations

Special drug designations promote vendors to come up with better drugs in the market, which extends the product offerings to patients and their adherence to therapeutic alternatives. This, in turn, drives the market growth.

Adverse effects associated with available drugs

The drugs that are available in the market include glucocorticoids and mineralocorticoids, which are associated with harmful side effects. These side effects exert a negative impact on the quality of life of the patients and reduce their willingness to continue treatment with the drugs.

For the detailed list of factors that will drive and challenge the growth of the Addison's disease therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Various companies are focusing on investing in R&D of the medicines for curing rare and orphan diseases, including Addison's disease, along with the chronic illnesses such as central nervous system (CNS) disorders, and cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31202

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Oral drugs - Market size and forecast 2018-2023
  • Parenteral drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of vendors classification

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global rare diseases therapeutics market
  • Exhibit 02: Segments of global rare diseases therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Oral drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Oral drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Parenteral drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Parenteral drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Reformulated corticosteroids
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 49: Bristol-Myers Squibb Company - Business segments
  • Exhibit 50: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 51: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 52: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 53: Merck & Co. Inc. - Vendor overview
  • Exhibit 54: Merck & Co. Inc. - Business segments
  • Exhibit 55: Merck & Co. Inc. - Organizational developments
  • Exhibit 56: Merck & Co. Inc. - Geographic focus
  • Exhibit 57: Merck & Co. Inc. - Segment focus
  • Exhibit 58: Merck & Co. Inc. - Key offerings
  • Exhibit 59: Novartis AG - Vendor overview
  • Exhibit 60: Novartis AG - Business segments
  • Exhibit 61: Novartis AG - Organizational developments
  • Exhibit 62: Novartis AG - Geographic focus
  • Exhibit 63: Novartis AG - Segment focus
  • Exhibit 64: Novartis AG - Key offerings
  • Exhibit 65: Pfizer Inc. - Vendor overview
  • Exhibit 66: Pfizer Inc. - Business segments
  • Exhibit 67: Pfizer Inc. - Organizational developments
  • Exhibit 68: Pfizer Inc. - Geographic focus
  • Exhibit 69: Pfizer Inc. - Segment focus
  • Exhibit 70: Pfizer Inc. - Key offerings
  • Exhibit 71: Takeda Pharmaceutical Company Limited - Vendor overview
  • Exhibit 72: Takeda Pharmaceutical Company Limited - Business segments
  • Exhibit 73: Takeda Pharmaceutical Company Limited - Organizational developments
  • Exhibit 74: Takeda Pharmaceutical Company Limited - Geographic focus
  • Exhibit 75: Takeda Pharmaceutical Company Limited - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing
  • Exhibit 77: Definition of vendors classification
Back to Top